Compare AbbVie Inc (ABBV) vs Micron Technology, Inc. (MU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Micron Technology, Inc. — how do they compare? AbbVie Inc trades at $253.85 (market cap $449.91B), while Micron Technology, Inc. trades at $940.88 (market cap $1.06T). The key difference: Micron Technology, Inc. is far larger — about 2.4× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MU | |
|---|---|---|
Market Cap | $449.91B | $1.06T |
Sector | Health | Technology |
52-Week High | $261.07 | $1.21K |
52-Week Low | $184.85 | $104.88 |
Enterprise Value | $513.38B | $1.04T |
Dividend Yield | 2.72% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Micron Technology (MU) trades at $938.38, down 3.81% amid a sector-wide chip stock selloff, despite strong fundamentals including a 22.84% net margin and three consecutive quarterly earnings beats. The stock shows a bullish technical trend with support near $933, while analyst consensus remains strongly positive with a $1,540 price target. Recent news highlights AI-driven demand and new supply deals with Ford and GM, though competition and cyclicality pose risks.
Outlook is positive given robust earnings growth and AI memory demand, but investors face volatility from memory market cycles and competitive pressures. The stock offers upside to analyst targets if execution continues, yet macroeconomic and sector rotations could drive near-term swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
